ERNA · Ernexa Therapeutics Inc. · Financials
$4.17
+0.15 (+3.61%)
At close · Sep 11
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$6.80M
Shares
1.63M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$582K
+755.9%
FY2024
Net Income
-$14.08M
+68.4%
FY2025
Gross Margin
83.51%
+330.6pp
FY2024
Operating Margin
-2693.13%
+28387.8pp
FY2024
Diluted EPS
-$56.00
+95.4%
FY2025
Operating Cash Flow
-$7.02M
+55.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $582K | $68K | $0 | — | $5.8M | $19.81M | $23.34M | $21.27M | $22.31M | $24.52M | $26.05M | $23.75M | $24.06M | $23.87M | $25.31M | |
| — | — | $96K | $236K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $486K | -$168K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 83.51% | -247.06% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $6.42M | $4.16M | $4.6M | $5.92M | $10.39M | $12.71M | $2000 | $26K | $72K | $139K | — | — | — | — | — | — | — | |
| $5.32M | $5.16M | $13.13M | $14.59M | $16.84M | $14.72M | $3.3M | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $8.09M | $13.18M | $14.46M | $15.59M | $16.46M | $18.06M | $18.37M | $16.22M | $18.25M | $20.45M | $18.91M | |
| — | — | — | — | — | — | — | — | $29K | $29K | $50K | $50K | $181K | $418K | $378K | $614K | — | |
| -$345K | $65K | $139K | $84K | $161K | $117K | $98K | $2.88M | $2.76M | $2.32M | $2.89M | $3.1M | $2.75M | $2.85M | $2.88M | $3.26M | $3.2M | |
| $13.78M | $9.32M | $16.16M | $20.97M | $33.22M | $113.73M | $7.25M | $21.57M | $23.13M | $22.68M | $24.59M | $31.41M | $30.79M | $24.87M | $25.13M | $27.15M | $25.63M | |
| -$13.78M | -$9.32M | -$15.67M | -$21.14M | -$33.22M | -$113.73M | -$7.25M | -$1.76M | $203K | -$1.4M | -$2.28M | -$6.9M | -$4.74M | -$1.12M | -$1.06M | -$3.28M | -$325K | |
| — | — | -2693.13% | -31080.88% | — | — | -124.97% | -8.9% | 0.87% | -6.59% | -10.21% | -28.12% | -18.21% | -4.71% | -4.41% | -13.72% | -1.28% | |
| -$14.13M | -$9.25M | -$15.54M | -$21.05M | -$33.06M | -$113.62M | -$7.15M | $1.12M | $2.97M | $915K | $609K | -$3.79M | -$2M | $1.73M | $1.82M | -$16K | $2.88M | |
| — | -$100K | -$6.8M | $614K | $30K | — | — | — | — | — | — | — | $223K | $26K | $44K | $52K | $101K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3000 | $3000 | $3000 | |
| $1.43M | -$4.81M | -$28.84M | -$536K | $8.68M | -$8.75M | -$43K | -$258K | -$526K | $391K | -$607K | -$319K | -$204K | $112K | -$16K | $20K | -$33K | |
| -$12.35M | -$14.13M | -$44.51M | -$21.67M | -$24.53M | -$122.48M | -$7.29M | -$2.02M | -$323K | -$1.01M | -$2.89M | -$7.21M | -$4.95M | -$1.01M | -$1.08M | -$3.26M | — | |
| -$96K | -$45K | $30K | -$3000 | $45K | $64K | $0 | $27K | -$64K | $66K | $38K | $12K | $84K | $46K | -$83K | $163K | $42K | |
| -$12.26M | -$14.08M | -$44.54M | -$21.67M | -$24.58M | -$122.55M | -$7.29M | -$2.05M | -$259K | -$1.08M | -$2.92M | -$7.23M | -$5.03M | -$1.05M | -$995K | -$3.42M | -$400K | |
| — | — | -7652.75% | -31864.71% | — | — | -125.71% | -10.34% | -1.11% | -5.06% | -13.1% | -29.47% | -19.31% | -4.43% | -4.13% | -14.32% | -1.58% | |
| — | -$14.1M | -$44.56M | -$21.68M | -$24.6M | -$122.56M | -$7.29M | -$2.06M | -$275K | -$1.09M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | -$4.44M | -$1.98M | -$404K | -$955K | -$2.87M | -$7.53M | -$5.18M | -$1.19M | -$949K | -$3.48M | -$317K | |
| USD/shares | $6.60 | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $6.60 | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 252.28K | 36.4K | 14.17K | 8136 | 5773.3333 | 2345.0667 | 0.1917 | 0.1792 | 162.8 | 126.8667 | 122.5333 | 5.8387 | 4797.4667 | 4.6027 | 4026.8 | 4008.9333 |
| shares | — | 252.28K | 36.4K | 14.17K | 8136 | 5773.3333 | 2345.0667 | 0.1917 | 0.1792 | 162.8 | 126.8667 | 122.5333 | 5.8387 | 4797.4667 | 4602.6667 | 4.0268 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.90×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.12×
Peer medians compare against the 182 similar-size Biotechnology companies (of 536 listed).